Mirinaviciute Grazina, Kristensen Erle, Nakstad Britt, Flem Elmira
From the *Department of Infectious Diseases Epidemiology and Modeling, Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway; †Department of Pediatrics and Adolescent Medicine, Akershus University Hospital, Nordbyhagen, Norway; ‡Institute of Clinical Medicine Campus AHUS Division of Medicine and Laboratory Sciences, University of Oslo, Oslo, Norway; and §Section for Research and Development, Department of Pediatrics and Adolescent Medicine, Akershus University Hospital, Nordbyhagen, Norway.
Pediatr Infect Dis J. 2017 Nov;36(11):1032-1038. doi: 10.1097/INF.0000000000001656.
Norway does not currently implement universal varicella vaccination in childhood. We aimed to characterize health care burden of varicella in Norway in the prevaccine era.
We linked individual patient data from different national registries to examine varicella vaccinations and varicella-coded primary care consultations, hospitalizations, outpatient hospital visits, deaths and viral infections of central nervous system in the whole population of Norway during 2008-2014. We estimated health care contact rates and described the epidemiology of medically attended varicella infection.
Each year approximately 14,600 varicella-related contacts occurred within primary health care and hospital sector in Norway. The annual contact rate was 221 cases per 100,000 population in primary health care and 7.3 cases per 100,000 in hospital care. Both in primary and hospital care, the highest incidences were observed among children 1 year of age: 2,654 and 78.1 cases per 100,000, respectively. The annual varicella mortality was estimated at 0.06 deaths per 100,000 and in-hospital case-fatality rate at 0.3%. Very few (0.2-0.5%) patients were vaccinated against varicella. Among hospitalized varicella patients, 22% had predisposing conditions, 9% had severe-to-very severe comorbidities and 5.5% were immunocompromised. Varicella-related complications were reported in 29.3% of hospitalized patients. Varicella zoster virus was the third most frequent virus found among 16% of patients with confirmed viral infections of central nervous system.
Varicella causes a considerable health care burden in Norway, especially among children. To inform the policy decision on the use of varicella vaccination, a health economic assessment of vaccination and mathematical modeling of vaccination impact are needed.
挪威目前未在儿童期实施普遍的水痘疫苗接种。我们旨在描述疫苗接种前时代挪威水痘的医疗负担特征。
我们将来自不同国家登记处的个体患者数据相链接,以检查2008年至2014年期间挪威全体人口的水痘疫苗接种情况以及以水痘编码的初级保健会诊、住院治疗、门诊就诊、死亡和中枢神经系统病毒感染情况。我们估计了医疗接触率,并描述了接受医疗护理的水痘感染的流行病学特征。
挪威每年在初级卫生保健和医院部门发生约14,600例与水痘相关的接触。初级卫生保健中的年接触率为每10万人221例,医院护理中的年接触率为每10万人7.3例。在初级卫生保健和医院护理中,1岁儿童的发病率最高:分别为每10万人2,654例和78.1例。估计水痘年死亡率为每10万人0.06例,住院病死率为0.3%。极少(0.2 - 0.5%)患者接种过水痘疫苗。在住院的水痘患者中,22%有诱发因素,9%有严重至极严重的合并症,5.5%免疫功能低下。29.3%的住院患者报告了与水痘相关的并发症。水痘带状疱疹病毒是在16%确诊中枢神经系统病毒感染的患者中发现的第三常见病毒。
水痘在挪威造成了相当大的医疗负担,尤其是在儿童中。为了为水痘疫苗接种的政策决策提供依据,需要对疫苗接种进行健康经济评估以及对疫苗接种影响进行数学建模。